intestinal perforation
[대역어] None
[용어속성] Term
[용어속성] Term
Intestinal mucormycosis in a patient with COVID-19: A case report
Case Reports
[키워드] coronavirus
fungal co-infections
intestinal perforation
Mucormycosis.
[DOI] 10.4103/IJPM.IJPM_1436_20 PMC 바로가기 [Article Type] Case Reports
[DOI] 10.4103/IJPM.IJPM_1436_20 PMC 바로가기 [Article Type] Case Reports
Surge of Typhoid Intestinal Perforations as Possible Result of COVID-19–Associated Delays in Seeking Care, Madagascar
Dispatch
[키워드] Salmonella enterica serovar Typhi
coronavirus disease
COVID-19
Delay
healthcare
incidence
increase in
intestinal perforation
intestinal perforations
madagascar
occurred
pandemic
Perforation
respiratory infections
Result
SARS-CoV-2
seeking
severe acute respiratory syndrome coronavirus 2
Surveillance
typhoid
viruses
zoonoses
[DOI] 10.3201/eid2712.210516 PMC 바로가기 [Article Type] Dispatch
[DOI] 10.3201/eid2712.210516 PMC 바로가기 [Article Type] Dispatch
A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial
COVID19에 감염된 종양-혈액학적 환자에서 호흡 부전 진행을 예방하기 위한 바리시티닙의 효능을 평가하기 위한 I/II상 임상 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
AAK1
absence
activator
Acute respiratory failure
Administered
administration
Adverse
adverse events
affected
alkaline phosphatase
All participants
allergy
Alpha
alpha error
angina pectoris
Antibiotics
appearance
ARDS
Arm
assigned
AST/ALT
Baricitinib
baseline
beta error
Bilirubin
Blinding
Blood
Breastfeeding
can be used
candidate
Candidates
capture
Cardiac arrhythmia
carried
change
clearance
clinical
clinical condition
clinical suspicion
clinical trials
Coagulation
Cohort
Common Terminology Criteria
Comorbidity
Complete
completion
Compliance
congestive heart failure
control arm
Controlled trial
corticoid
Corticosteroids
COVID19
creatinine
creatinine clearance
CRP
D-dimer
Day
Deep venous thrombosis
description
Deterioration
Dexamethasone
dimer
discharge
discretion
disease
dissemination
diverticulitis
dose
dropout rate
Duration of therapy
ECMO
Efficacy
electronic case report form
element
eligibility criteria
Enrollment
evaluate
exclusion criteria
expected
experimental arm
extracorporeal membrane oxygenation
febrile neutropenia
ferritin
followed by
form
fraction
Gas exchange
greater
HBV
HCV
hemodynamic instability
High-flow nasal cannula
HIV
HIV infection
ICU
immobilization
immunological
impossibility
incidence
include
indication
Infection
infection with SARS-CoV-2
Inflammatory response
interfere
interferon
Interim
interim analysis
interleukin
interleukin 6
interstitial pneumonia
Intervention
intestinal perforation
Invasive mechanical ventilation
investigational agent
investigator
jak inhibitors
Jak-STAT
Laboratory
laboratory parameter
Laboratory parameters
LDH
less
limit
limits
management
mechanical ventilation
medical history
Medicine
meet
Methylprednisolone
Mild ARDS
Mortality
multi organ failure
nasal
nasal cannula
need for oxygen
neutropenia
neutrophil
Neutrophils
Non-invasive
number
objective
on mechanical ventilation
oncological patients
onset of symptom
open
open label
oral medication
organ dysfunction
Organ failure
outcome
oxygen
oxygen support
PaFi
participant
Participants
Participation
pathogen
Pathogens
pathway
Patient
patients
performance status
performed
phase
Phase 1
Phase 2
Phase I
phosphatase
platform
Pneumonia
poor prognosis
positive
Prednisone
pregnancy test
pregnant
prejudice
Prevent
progression
Prophylaxis
Protein
protein kinase
protocol
Psychiatric
psychiatric illness
Pulmonary embolism
radiological
randomisation
randomised
randomised controlled trial
randomization
Randomized
Randomized controlled trial
receive
receptor
recruitment
REDCap
REDcap platform
reduce
reduced
Remdesivir
removal
report
reported
required
respiratory
Respiratory failure
Respiratory function
respiratory insufficiency
respiratory tract
Sample size
SARS-CoV-2
SARS-CoV2
SARS-CoV2 infection
Secondary objectives
Sepsis
severe adverse event
severe adverse events
severe pneumonia
severe respiratory failure
Spain
Spanish
Standard of care
STAT
status
study enrollment
Study protocol
supplemental oxygen requirement
supplemental oxygen requirements
supplementary material
Support
surgical
surgical intervention
Symptom
symptomatic
Tablet
Therapies
therapy
thromboembolic disease
thrombosis
Tocilizumab
total bilirubin
Toxicity
Transcription
transducer
Treatment
treatment period
Trial
unstable angina
use of corticosteroid
Venous thrombosis
Version
viral endocytosis
website
Withdrawal
worsening
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-021-05072-4 PMC 바로가기 [Article Type] Letter
Pneumatosis Intestinalis in COVID-19: Case Series
Gastroenterology
[키워드] Acute kidney injury
Administered
anticoagulation
arterial pH
bowel
case sery
Clinical characteristics
clinically
collected
conducted
coronavirus disease
COVID-19
demographics
Diagnosis
Hospitalization
IL-6
inhibitor
intensive care unit
interleukin-6
Intervention
intestinal perforation
majority
morbidity
morbidity and mortality
Mortality
New York
nine
occurred
outcome
Oxygen requirement
Patient
pneumatosis
pneumatosis cystoides intestinalis
portal
Radiographic
serum
serum lactate
Sery
severe acute respiratory syndrome coronavirus 2
state
subsequent
System
tertiary care center
treatment regimen
vasopressor requirement
venous
[DOI] 10.7759/cureus.10991 PMC 바로가기 [Article Type] Gastroenterology
[DOI] 10.7759/cureus.10991 PMC 바로가기 [Article Type] Gastroenterology
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 24 hour
7-point ordinal scale
absence
addition
administration
Admission
ALT
anticipated
assigned
AST
baseline
biological parameters
candidate
Care
clinical
Clinical research
clinical status
clinical trial
clinician
Comorbidity
conditions
Control
control arm
control group
Coronavirus infections
Council
COVID 19
COVID-19
COVID-19 infection
criteria
current
D-dimer
Day
death rate
decrease
discharge
dissemination
dose
drug
Duration
early stage
Efficacy
element
ELISA
enrolment
EudraCT
European
evaluate
exclusion criteria
exploratory
extracorporeal membrane oxygenation
Frame
harmonization
hospitalisation
hospitalised
hospitalised patient
hyperinflammatory status
hypersensitivity
Hypothesis
identify
IL-6
IL-6 levels
IL-6 receptor inhibitors
IL-6R
In-hospital
incidence
Inclusion
inclusion criteria
independent
Infection
Informed
inhibitor
interstitial pneumonia
Intervention
intervention group
intestinal perforation
Invasive mechanical ventilation
investigator
investigator-initiated
lactation
Local
marker
measure
mechanical ventilation
moderate
moderate-severe
neutrophil count
Non-invasive
non-invasive ventilation
number
number of death
objective
Open label trial
outbreak
outcome
oxygen
Oxygenation
pandemic
participant
pathogen
patients treated
performed
Platelet
Pneumonia
positive
positive RT-PCR
Positive test
Prednisone
Presence
Prevent
progression
protocol
random
randomisation
randomised
randomised controlled trial
receive
recruited
recruitment
Registered
reported
requiring supplemental oxygen
responsible
routine clinical practice
RT-PCR
SAEs
Sample size
sarilumab
SARS-CoV-2
SARS-COV-2 infection
score
Sepsis
Serious Adverse Event
serum
Severe COVID-19 Infection
single center
single dose
Spain
Standard
Standard of care
status
Study protocol
Subcutaneous
subcutaneous injection
the patient
therapy
treated
Treatment
treatment arm
treatment with tocilizumab
Trial
ULN
union
unit
verbal
website
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04588-5 PMC 바로가기 [Article Type] Letter